Enterprise-wide Evidentiary Architecture for Gilead Sciences & Kite Pharma
A unified RWD backbone to accelerate evidence generation across HIV, CAR-T, and MASH/NASH.
The Challenge
Scaling Evidence Generation in the Age of AI
The Transparency Gap in Legacy Analytics
Relying on legacy data aggregators often results in “black-box” analytics that lack the “glass-box” transparency and visible code generation required for successful HTA submissions, ICER reviews, and peer-reviewed publications.
Disconnected Patient Journeys in Complex TAs
To support high-stakes launches and protect established brands in HIV and Cell Therapy, teams need more than a simple data feed; they require a research-specific architecture that bridges Care Gaps and identifies at-risk populations using clinical-grade thresholds.
The Evidentiary Rigor Deficit
Generating regulatory-grade evidence requires solving for persistent challenges like missing cost data and enrollment gaps, necessitating a unified RWD backbone that ensures every analysis is auditable, reproducible, and representative.
Solving with Komodo
Multi-Functional Evidence Solutions
Clinical Development & Feasibility
Streamlined CAR-T Phase 2 protocols with data-driven feasibility modeling to pinpoint high-density patient clusters and ideal trial sites.
Medical Affairs & Evidence Generation
Build peer-review-ready outcomes for Yescarta and Tecartus. By using transparent, reproducible code, we provided the rigorous data needed to satisfy ICER and payer requirements.
Outcomes Research
Accelerate treatment pattern research from weeks to minutes. Using the Marmot platform, teams can now run complex hypothesis testing and descriptive statistics in real-time.
Health Equity & Access
Monitor treatment uptake through a health equity lens, utilizing patient data that mirrors the U.S. Census to ensure no community is left behind.
The Komodo Impact
Trusted Evidence for unified RWD
Accelerated Evidence Life Cycle
Reduce specialty data integration timelines by 4–9 months via pre-linked lab and EHR datasets.
Enhanced Economic Modeling:
Achieve a 95%+ cost fill rate through proprietary imputation, enabling accurate HCRU and “Total Cost of Care” analyses for MASH and CAR-T.
Transparency and Rigor
Every analysis in Marmot features traceable code generation, ensuring all RWE is transparent, reproducible, and auditable for regulatory stakeholders.
Track complex HIV and Oncology journeys with an average of 12 months of continuous enrollment across all payer types.
Resources
Read more about how Komodo’s robust product suite can help you unlock your team’s expertise and accelerate decision-making across the enterprise.
AI Reliability Guide
Guide
Komodo Health’s HEOR Methodology
WHITE PAPER
How Marmot Delivers Enterprise Wide ROI
Perspectives
Gain Your Velocity Advantage in Evidence Generation
The standard for RWE has evolved. Transition from manual data cycles to an AI-driven evidentiary foundation. Experience a higher standard of rigor for HIV, CAR-T, and MASH/NASH in H2 FY27.